Missouri is currently home to 1899 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Recruiting
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Specialty Clinical Research of St. Louis, Saint Louis, Missouri
Conditions: High-Risk Non-Muscle-Invasive Bladder Cancer
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Recruiting
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional saf... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Saint Louis, Missouri
Conditions: Cerebral Amyloid Angiopathy
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
Recruiting
This is a multicenter retrospective comparative cohort study. The index surgery for this study is primary or revision long-segment posterior thoracolumbar (TL) instrumented fusion using either a supplementary rod construct or a dual-rod construct. Eligible patients who already had index surgery, will be identified for enrollment through a review of medical records of the participating surgeons at the study sites.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/15/2025
Locations: Washington University in St. Louis, School of Medicine, Saint Louis, Missouri
Conditions: Spinal Fusion
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: University of Missouri, Columbia, Missouri
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients
Recruiting
With modern therapy, the survival rate for pediatric brain tumor patients has significantly improved, with over 70% of patients surviving their disease. However, this progress often comes at the cost of substantial morbidity, with cognitive deficits being the primary obstacle to independent living. Robust predictors of cognitive decline and a comprehensive understanding of the underlying mechanisms of cognitive injury remain elusive. This study will prospectively investigate alterations in brain... Read More
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
07/15/2025
Locations: Washington University School of Medicine/Saint Louis Children's Hospital, Saint Louis, Missouri
Conditions: Brain Tumor, Primary
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/15/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
CTSN Embolic Protection Trial
Recruiting
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/15/2025
Locations: Saint Luke's Hospital of Kansas City, Kansas City, Missouri
Conditions: Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Recruiting
This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Cancer, Cancer of the Breast
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Recruiting
This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors. Sunitinib malate is in a class of medications called kinase inhibitors and a form of targeted therapy that blocks the action of abnormal proteins called VEGFRs that signal tumor cells to multiply. This helps stop or slow the spread of tumor cells. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri
Conditions: Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage IV Pancreatic Neuroendocrine Tumor AJCC v8, Unresectable Pancreatic Neuroendocrine Tumor
Interhemispheric Connectivity and Compensation
Recruiting
The goal of this study is to determine which parts of the brain make it possible for some people to move skillfully with their left non-dominant hand.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Peripheral Nerve Injury Upper Limb, Healthy
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Recruiting
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, a... Read More
Gender:
ALL
Ages:
Between 3 years and 39 years
Trial Updated:
07/15/2025
Locations: St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Diffusion Basis Spectrum Imaging of the Prostate
Recruiting
Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Prostate Cancer